TIDMSTX

RNS Number : 6311N

Shield Therapeutics PLC

30 September 2021

Shield Therapeutics plc

("Shield" or the "Group")

Block Listing 6 Monthly Return

Date: 30 September 2021

 
  Name of applicant:                                                     SHIELD THERAPEUTICS PLC 
 Name of scheme:                                                         S hield Therapeutics Retention Share Plan 
                                                                        ---------------------------------------------- 
 Period of return:                             From:                     01 April 2021      To:   30 September 2021 
                                              ------------------------  -----------------  ----  --------------------- 
 Balance of unallotted securities under scheme(s) from previous 
  return:                                                                39,794 
                                                                        ---------------------------------------------- 
 Plus: The amount by which the block scheme(s) has been increased        NIL 
 since the date of the last 
 return (if any increase has been applied for): 
                                                                        ---------------------------------------------- 
 Less: Number of securities issued/allotted under scheme(s) during       NIL 
 period (see LR3.5.7G): 
                                                                        ---------------------------------------------- 
 Equals: Balance under scheme(s) not yet issued/allotted at end of 
  period:                                                                39,794 
                                                                        ---------------------------------------------- 
 
 
 
 Name of applicant:                                         SHIELD THERAPEUTICS PLC 
 Name of scheme:                                            Shield Therapeutics plc 2016 Company Share Option Plan 
                                                           ----------------------------------------------------------- 
 Period of return:                From:                     01 April 2021           To:     30 September 2021 
                                 ------------------------  ----------------------  ------  --------------------------- 
 Balance of unallotted securities under scheme(s) from 
  previous return:                                          388,079 
                                                           ----------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has been     NIL 
 increased since the date of the last 
 return (if any increase has been applied for): 
                                                           ----------------------------------------------------------- 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):                   -47,059 
                                                           ----------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet issued/allotted 
  at end of period:                                         341,020 
                                                           ----------------------------------------------------------- 
 
 
 
  Name of applicant:                                      SHIELD THERAPEUTICS PLC 
 Name of scheme:                                          The Shield Therapeutics plc 2016 Long Term Incentive Plan 
                                                         ------------------------------------------------------------- 
 Period of return:              From:                     01 April 2021            To:     30 September 2021 
                               ------------------------  -----------------------  ------  ---------------------------- 
 Balance of unallotted securities under scheme(s) from 
  previous return:                                        24,273 
                                                         ------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has been   NIL 
 increased since the date of the last 
 return (if any increase has been applied for): 
                                                         ------------------------------------------------------------- 
 Less: Number of securities issued/allotted under         NIL 
 scheme(s) during period (see LR3.5.7G): 
                                                         ------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period:                       24,273 
                                                         ------------------------------------------------------------- 
 
 
 
 Name of applicant:                                       SHIELD THERAPEUTICS PLC 
 Name of scheme:                                          Shield Therapeutics Retention and Performance Share Plan 
                                                         ------------------------------------------------------------- 
 Period of return:              From:                     01 April 2021            To:     30 September 2021 
                               ------------------------  -----------------------  ------  ---------------------------- 
 Balance of unallotted securities under scheme(s) from 
  previous return:                                        3,178,276 
                                                         ------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has been   NIL 
 increased since the date of the last 
 return (if any increase has been applied for): 
                                                         ------------------------------------------------------------- 
 Less: Number of securities issued/allotted under         NIL 
 scheme(s) during period (see LR3.5.7G): 
                                                         ------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period:                       3,178,276 
                                                         ------------------------------------------------------------- 
 
 
 
 Name of contact:                Lucy Huntington-Bailey 
 Telephone number of contact:    +44 (0) 191 511 8500 
                                ----------------------- 
 

For further information, please contact:

 
 Shield Therapeutics plc                                     +44 (0) 191 511 8500 
 Greg Madison (CEO) 
  Hans-Peter Rudolf (CFO) 
 
 Peel Hunt LLP - Nominated Adviser & Joint 
  Broker                                                     +44 (0) 20 7148 8900 
 James Steel / Christopher Golden 
 
 finnCap Ltd - Joint Broker                                  +44 (0) 20 7220 0500 
 Geoff Nash / Alice Lane/ George Dollemore 
 
 Walbrook PR - Financial PR & IR Adviser                     +44 (0) 20 7933 8780 
 Paul McManus / Lianne Cawthorne/ Alice                  or shield@walbrookpr.com 
  Woodings 
 
 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer(R) in the US. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREAKNEDAEFEFA

(END) Dow Jones Newswires

September 30, 2021 12:29 ET (16:29 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Nov 2021 a Dic 2021 Haga Click aquí para más Gráficas Shield Therapeutics.
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Dic 2020 a Dic 2021 Haga Click aquí para más Gráficas Shield Therapeutics.